Contingent liability for essentialis purchase price
13,846
20,327
-
-
Accrued clinical trial site costs
-
-
-
1,863
Other current liabilities
24,931
18,198
17,163
5,512
Total current liabilities
58,049
61,363
33,253
20,943
Contingent liability for essentialis purchase price
-
-
19,473
18,859
Long-term debt, net
49,871
49,863
49,854
49,845
Long-term lease liabilities
3,243
1,964
2,112
2,248
Other long-term liabilities
1,425
525
398
271
Total liabilities
112,588
113,715
105,090
92,166
Common stock, 0.001 par value, 100,000,000 shares authorized, 51,718,149 and 52,286,881 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
52
52
54
50
Additional paid-in-capital
897,578
881,018
969,119
740,746
Accumulated other comprehensive income (loss)
-1,838
415
360
85
Accumulated deficit
-399,992
-431,370
-474,728
-500,741
Total stockholders equity
495,800
450,115
494,805
240,140
Total liabilities and stockholders equity
608,388
563,830
599,895
332,306
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.